Table E1.
Features of the participants in the included studies. Data represent the number of participants (%), the mean ± SD, or the median (35th, 75th percentile). EFDs = episode free days.
| Feature | PEAK N = 285 | AIMS N = 238 | MIST N = 278 | APRIL N = 607 | INFANT N = 300 |
|---|---|---|---|---|---|
| Age at enrollment (months) | 36.0 ± 7.0 | 29.5 ± 12.8 | 34.9 ± 11.2 | 41.5 ± 16.5 | 39.9 ± 13.2 |
| Males | 177 (62.1) | 154 (64.7) | 192 (69.1) | 365 (60.1) | 179 (59.7) |
| Race/ethnicity | |||||
| Non-Hispanic White | 152 (53.3) | 133 (55.9) | 113 (40.6) | 215 (35.4) | 96 (32.0) |
| Non-Hispanic Black | 38 (13.3) | 24 (10.1) | 39 (14.0) | 142 (23.4) | 93 (31.0) |
| Hispanic | 55 (19.3) | 59 (24.8) | 84 (30.2) | 183 (30.1) | 72 (24.0) |
| Other | 40 (14.0) | 22 (9.2) | 42 (15.1) | 67 (11.0) | 39 (13.0) |
| Current tobacco smoke exposure | 111 (38.9) | 24 (10.1) | 122 (43.9) | 240 (39.5) | 110 (36.7) |
| Current cat or dog in the home | 129 (45.3) | 107 (45.0) | 129 (46.4) | 280 (46.1) | 139 (46.3) |
| Emergency department or urgent care visit (past year) | 133 (46.7) | 96 (40.3) | 170 (61.2) | 582 (95.9) | 261 (87.0) |
| Hospitalization (past year) | 20 (7.0) | 19 (8.0) | 53 (19.1) | 82 (13.5) | 65 (21.7) |
| Eczema (ever) | 148 (51.9) | 89 (37.4) | 146 (52.5) | 328 (54.0) | 160 (53.3) |
| Parent with asthma (ever) | 184 (64.6) | 106 (44.5) | 171 (61.5) | 314 (51.7) | 178 (59.3) |
| Blood eosinophils (%)1 | 3.2 (2.0, 5.6) | 3.5 (2.0, 5.6) | 3.1 (2.0, 6.0) | 3.0 (2.0, 5.6) | 3.5 (2.0, 6.0) |
| Quartile 1 | 93 (33.3) | 69 (30.0) | 96 (36.9) | 194 (34.2) | 76 (29.3) |
| Quartile 2 | 44 (15.8) | 43 (18.7) | 35 (13.5) | 112 (19.7) | 43 (16.6) |
| Quartile 3 | 86 (30.8) | 68 (29.6) | 70 (26.9) | 150 (26.4) | 80 (30.9) |
| Quartile 4 | 56 (20.1) | 50 (21.7) | 59 (22.7) | 112 (19.7) | 60 (23.2) |
| Total serum IgE (IU/mL) | 44.0 (14.0, 112.0) | 46.7 (10.0, 138.0) | 58.0 (21.0, 186.0) | 51.1 (14.6, 170.3) | 70.0 (22.0, 208.0) |
| Quartile 1 | 72 (27.2) | 71 (32.4) | 56 (21.5) | 144 (26.2) | 54 (18.7) |
| Quartile 2 | 74 (27.9) | 46 (21.0) | 72 (27.6) | 140 (25.5) | 66 (22.8) |
| Quartile 3 | 68 (25.7) | 54 (24.7) | 60 (23.0) | 123 (22.4) | 83 (28.7) |
| Quartile 4 | 51 (19.2) | 48 (21.9) | 73 (28.0) | 143 (26.0) | 86 (29.8) |
| Positive aeroallergen tests2 | |||||
| None | 116 (40.7) | 127 (53.4) | 117 (42.1) | 374 (61.6) | 174 (58.0) |
| 1–2 | 65 (22.8) | 58 (24.4) | 64 (23.0) | 133 (21.9) | 73 (24.3) |
| 3 or more | 104 (36.5) | 53 (22.3) | 97 (34.9) | 100 (16.5) | 53 (17.7) |
| % of positive aeroallergens | 16.9 ± 19.9 | 11.1 ± 16.2 | 18.5 ± 24.0 | 12.0 ± 21.0 | 14.4 ± 23.9 |
| Positive food allergen tests2 | |||||
| None | 185 (64.9) | 178 (74.8) | 183 (65.8) | 366 (60.3) | 170 (56.7) |
| 1–2 | 65 (22.8) | 41 (17.2) | 42 (15.1) | 103 (17.0) | 51 (17.0) |
| 3 | 35 (12.3) | 19 (8.0) | 53 (19.1) | 138 (22.7) | 79 (26.3) |
| % of positive foods | 17.2 ± 27.2 | 11.8 ± 23.0 | 21.5 ± 33.9 | 24.2 ± 33.7 | 29.3 ± 36.4 |
| EFDs (average number/week during study run-in period) | 5.1 ± 1.7 | 5.8 ± 1.3 | 4.8 ± 2.1 | 5.4 ± 1.7 | 6.0 ± 1.2 |
| Albuterol inhalations (average number/week during study run-in period) | 1.0 ± 1.3 | 0.8 ± 2.0 | 0.5 ± 0.8 | 0.1 ± 0.1 | 1.7 ± 2.9 |
1
N = 1423; Absolute eosinophil counts were not available from the PEAK study. Quartiles were derived from eosinophil percentages.
2
Skin tests were considered positive if the prick resulted in a wheal with a mean diameter (mean of maximum and 90° midpoint diameters) that was at least 3 mm greater than that produced by the saline control. Specific IgE tests were considered positive if values were >0.34